Sunitinib alone or in combination with chemotherapy for the treatment of advanced breast cancer: A systematic review and meta-analysis.

about

Sunitinib alone or in combination with chemotherapy for the treatment of advanced breast cancer: A systematic review and meta-analysis.

Item

http://www.wikidata.org/entity/Q38950248

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Sunitinib alone or in combinat ...... atic review and meta-analysis.

@en

type

Item

label

Sunitinib alone or in combinat ...... atic review and meta-analysis.

@en

prefLabel

Sunitinib alone or in combinat ...... atic review and meta-analysis.

@en

P1476

Sunitinib alone or in combinat ...... atic review and meta-analysis.

@en

P2093

Ahmed Menshawy

http://www.w3.org/2001/XMLSchema#string

Ahmed Omar

http://www.w3.org/2001/XMLSchema#string

Gehad El Ashal

http://www.w3.org/2001/XMLSchema#string

Omnya Osama

http://www.w3.org/2001/XMLSchema#string

P2860

Bias in meta-analysis detected by a simple, graphical test

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Triple-Negative Breast Cancer

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer.

Sunitinib significantly suppresses the proliferation, migration, apoptosis resistance, tumor angiogenesis and growth of triple-negative breast cancers but increases breast cancer stem cells.

Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer.

Age-specific trends of survival in metastatic breast cancer: 26 years longitudinal data from a population-based cancer registry in Stockholm, Sweden.

Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial.

Soluble KIT correlates with clinical outcome in patients with metastatic breast cancer treated with sunitinib

P304

91-101

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

meta-analysis

P356

10.3233/BD-160218

http://www.w3.org/2001/XMLSchema#string

P433

2-3

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Ahmed Negida, MBBCh

Esraa Ghanem

Ahmed Elgebaly

P577

2016-05-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27612040

http://www.w3.org/2001/XMLSchema#string